% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • vvvvvvrebel89130 vvvvvvrebel89130 Sep 5, 2013 8:19 AM Flag

    brean still with target of $13; says reject deal

    Astex Pharmaceuticals' buyout offer by Otsuka too low, says Brean Capital
    Brean Capital believes Otsuka's $8.50 per share buyout offer for Astex Pharmaceuticals is too low and does not fully reflect the value of Dacogen royalties, SGI-110 potential, or its portfolio of partnered compounds. The analyst believes Astex should reject any offer below $13 per share and reiterates its Buy rating and $13 price target.

    Sentiment: Strong Buy